HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Allergy & Immunology
Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Frontiers
May 28, 2026
Oncology
Meta-analysis
Systematic review and meta-analysis on neoadjuvant selection and liver transplantation for perihilar cholangiocarcinoma
Transplant selection may boost survival in bile duct cancer
This systematic review and meta-analysis synthesized evidence on protocol-based neoadjuvant selection and liver transplantation versus liver…
For a tough bile duct cancer, a new approach to choosing patients for transplant shows better long-term survival than surgery alone.
May 17, 2026
Allergy & Immunology
Sys. Review
Narrative review discusses cellular immunotherapy strategies for cholangiocarcinoma with noted limitations
New CAR T Cell Strategy May Beat Tough Liver Cancer
This narrative review examines cellular immunotherapy approaches for cholangiocarcinoma, including CAR-based therapies, multi-antigen design…
A new plan to fight bile duct cancer combines advanced cell therapy with other drugs to break through tumor defenses.
Frontiers
May 14, 2026
Oncology
Phase I
Lirafugratinib sequencing with futibatinib shows feasibility in FGFR2-driven cancers based on early-phase trial data
Can a new cancer drug work better if you switch to another drug after it stops?
This Phase I/II preprint trial evaluated lirafugratinib in 30 patients with FGFR2-driven cancers, including intrahepatic cholangiocarcinoma.
When a cancer drug stops working, switching to a different one might help because the two medicines attack the disease in slightly different…
Apr 16, 2026
Genetics & Precision Medicine
Meta-analysis
Meta-analysis of GEO datasets identifies specific gene expression alterations in aflatoxin-associated intrahepatic cholangiocarcinoma
Could aflatoxin exposure change specific genes in liver cancer, and what does that mean for prevention?
This meta-analysis examined genomic data from five Gene Expression Omnibus datasets to identify expression patterns in aflatoxin-induced int…
Liver cancer linked to aflatoxin exposure changes six specific genes, revealing new genetic pathways that could help doctors find early warn…
Frontiers
Apr 8, 2026